Twist incorporates Molcure AI into antibody discovery efforts

By The Science Advisory Board staff writers

Twist Bioscience announced that it has used Molcure's artificial intelligence (AI) technology to generate new cancer antibodies.

Molcure's AI platform is based on evolutionary molecular engineering, next-generation sequencing, and laboratory automation technologies. Together, the companies generated potent, binding antibodies to an undisclosed oncology target for Twist's internal pipeline of antibody candidates.

Twist and Molcure attribute the success in part to a technology agreement between the two firms under which they are working to develop new antibody targets, they said.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?